Drug name: Vismodegib + SN38


Related CSCTT Targets

ABCG2 [ref.1]Q9UNQ0

Vismodegib

Cas.no PubChem ID
879085-55-9 24776445
Known Target
Smoothened homologQ99835
Structure
...
Introduction
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). It acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.

SN38

Cas.no PubChem ID
86639-52-3 104842
Known Target
DNA topoisomerase 1P11387
Structure
...
Introduction
SN-38 (7-ethyl-10-hydroxycamptothecin) is the active metabolite of Irinotecan (CPT-11). SN-38 has been found to be 200–2000 times more cytotoxic than CPT-11, but has not been used as an anticancer drug due to its poor solubility in pharmaceutically acceptable solvents and low affinity to lipid membranes.

Reference

  • [1] Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.Zhang, Y., et al. (2009). Neoplasia 11(1): 96-101.
    19107236. [ 19107236 ]

Back to top